At that point IPIX is on to Ulcerative Colitis which I am very excited about. The phase 2 study of Brilacidin for Ulcerative Proctitis was fantastic even though the number of patients was small.
The Oral Mucosiditis phase 3 study is planned for 2022. "Additional work tied to starting, in 2022, a planned Phase 3 study of Brilacidin in Oral Mucositis is also in progress. We aim to maintain momentum across our clinical programs.”
IPIX has announced the stage 2 Ulcerative Colitis oral Brilacidin study should start in the next few months:
"Development work related to the formulation and manufacture of Brilacidin in capsule form is underway to support our Phase 2 trial in Ulcerative Colitis planned to commence this year."
In addition Alfasigma is making plans to study Brilacidin for Ulcerative Proctitis:
"Also in the pipeline, Alfasigma S.p.A. (“Alfasigma”)—the licensee of worldwide rights to develop, manufacture and commercialize rectally-administered Brilacidin for treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS)—notified the Company, in April, of its intentions to commence, in 2021, a Phase 2 multinational clinical trial of Brilacidin for UP/UPS. Alfasigma has placed an order with the Company for Brilacidin drug substance needed for the trial, which the Company is in the process of supplying. Per the licensing agreement, Innovation Pharma is eligible to receive $24 million in upfront and milestone p2022ayments, and a 6 percent royalty (net sales), upon the successful marketing of Brilacidin for UP/UPS."
News 
Market Data 
Discover 
